Greenberg Lab

Greenberg Lab

Greenberg group photo

Our Research

The Philip Greenberg lab at the Fred Hutchinson Cancer Research Center, a part of the Program on Immunology within the Clincal Research Division, focuses on both basic immunology and cancer immunobiology, and on the development and assessment of adoptive therapies with antigen-specific T cells targeting human malignancies and chronic infections.

The team is expert in identifying and validating candidate tumor antigen targets. They have made seminal advances in methods that are now widely employed for the identification and cloning of antigen-specific T cell receptors (TCRs), including high affinity TCRs, and for the rapid expansion of selected T cells in vitro. The Greenberg team is testing various other genetic engineering and cell production methods in preclinical models and moving toward new treatments, using naturally isolated or genetically-engineered T cells to effectively target cancer.

About the Program in Immunology

Investigators in The Program in Immunology are learning how immune cells respond to disease and how to safely enhance immune responses to better control, cure and potentially prevent cancers and other serious diseases. Nobel Prize-winning work on bone marrow transplantation began in the 1960s at the Fred Hutch, and provided the first definitive example of the immune system’s curative power. Fred Hutch researchers went on to show that donor immune T cells play a major role in successful transplant outcomes. In the 1990s, Program in Immunology investigators proved that antigen-specific T cells can be isolated, expanded in the laboratory and adoptively transferred to patients to augment T cell immunity. Techniques have since been developed to genetically engineer T cells to enhance their survival and their anti-cancer activities. And, studies are now showing how to use other types of immune cells to boost therapeutic immune responses. With our depth and breadth of expertise, we are advancing a detailed understanding of immunological processes and developing revolutionary immunotherapies to fight disease.